4-O-(2-Amino-2-deoxy-alpha-D-glucopyranosyl)-5-O-(beta-D-xylofuranosyl)-2-deoxy-D-streptamine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-O-(2-Amino-2-deoxy-alpha-D-glucopyranosyl)-5-O-(beta-D-xylofuranosyl)-2-deoxy-D-streptamine
• 英文别名: 5-amino-6-[4,6-diamino-2-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
• 化学式: C₁₇H₃₃N₃O₁₁
• 分子量: 455.5
• InChiKey: QTUJBJINYXOXOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  257
• 氢给体数：
  10
• 氢受体数：
  14

文献信息

• ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE
  申请人：Kett Warren Charles

  公开号：US20110190233A1

  公开（公告）日：2011-08-04

  The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.
• NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS
  申请人：Technion Research & Development Foundation Limited

  公开号：US20180064743A1

  公开（公告）日：2018-03-08

  A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.
• AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS
  申请人：Eloxx Pharmaceuticals Ltd.

  公开号：US20190016746A1

  公开（公告）日：2019-01-17

  Novel aminoglycosides, represented by Formulae I, Ia, III and IIIa, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
• METHODS, COMPOSITIONS, AND KITS FOR TREATING OCULAR DISEASES
  申请人：ELOXX PHARMACEUTICALS

  公开号：US20220008445A1

  公开（公告）日：2022-01-13

  Provided herein are methods of treating an ocular disease associated with one or more nonsense mutation in a subject using one or more amino-glycosides and/or derivatives thereof. The pharmaceutical compositions and kits containing one or more aminoglycosides and/or derivatives thereof for treating the ocular disease are disclosed.
• MODULAR SYNTHESIS OF AMINOGLYCOSIDES
  申请人：REVAGENIX, INC.

  公开号：US20220411456A1

  公开（公告）日：2022-12-29

  The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.